Protein-protein interaction (PPI) is a hot topic in clinical research as protein networking has a
major impact in human disease. Such PPIs are potential drugs targets, leading to the need …

Peptide-based drug discovery has experienced a significant upturn within the past decade
since the introduction of chemical modifications and unnatural amino acids has allowed for …

For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been
shown to exert oncogenic activity. These two proteins are best understood as negative …

Protein–protein interactions (PPIs) are implicated in the majority of cellular processes by
enabling and regulating the function of individual proteins. Thus, PPIs represent high-value …

A recent therapeutic strategy in oncology is based on blocking the protein–protein
interaction between the murine double minute (MDM) homologues MDM2/X and the tumor …

The growth inhibitory activity of p53 tumor suppressor is tightly regulated by interaction with
two negative regulatory proteins, murine double minute 2 (MDM2) and X (MDMX), which are …

During the three decades of cell-penetrating peptides era the superfamily of CPPs has
rapidly expanded, and the quest for new sequences continues. CPPs have been well …

Based on a combination of an Ugi four component reaction and a ring closing metathesis, a
library of novel artificial macrocyclic inhibitors of the p53–MDM2 interaction was designed …

The transcription factor p73, a member of the p53 tumor-suppressor family, regulates cell
death and also supports tumorigenesis, although the mechanistic basis for the dichotomous …

Protein flexibility poses a major challenge in binding site identification. Several
computational pocket detection methods that utilize small-molecule probes in molecular …